-0.96%
11.66%
15.75%
5.47%
2.49%
40.74%
18.75%
AI Spotlight on CTEC
Company Description
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide.It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes.The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes.
In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings.Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices.Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets.
The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers.It serves a range of customers, including healthcare providers, patients, and manufacturers.The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
Market Data
| Last Price | 247 |
| Change Percentage | -0.96% |
| Open | 248 |
| Previous Close | 249.4 |
| Market Cap ( Millions) | 5036 |
| Volume | 2960743 |
| Year High | 295.2 |
| Year Low | 211.8 |
| M A 50 | 231.83 |
| M A 200 | 237.1 |
Financial Ratios
| FCF Yield | 3.78% |
| Dividend Yield | 1.27% |
| ROE | 9.15% |
| Debt / Equity | 85.32% |
| Net Debt / EBIDTA | 270.35% |
| Price To Book | 3.83 |
| Price Earnings Ratio | 41.34 |
| Price To FCF | 26.49 |
| Price To sales | 2.84 |
| EV / EBITDA | 15.54 |
News
- Jan -29 - Discover Restore And 2 Other UK Stocks That May Be Trading Below Estimated Value
- Nov -14 - ConvaTec Group And 2 Other UK Stocks That May Be Priced Below Their Estimated Value
- Oct -15 - 3 UK Stocks That Could Be Trading Below Estimated Value
- Oct -09 - ConvaTec Group PLC (CNVVY) (H1 2024) Earnings Call Highlights: Strong Organic Growth and ...
- Sep -30 - September 2024's UK Stock Picks For Possible Value Investing
- Apr -15 - Convatec launches new Esteem Body™ with Leak Defense™
- Mar -06 - Health Care Roundup: Market Talk
- Nov -03 - Investors Will Want Emmi's (VTX:EMMN) Growth In ROCE To Persist
- Aug -22 - Is There An Opportunity With ConvaTec Group PLC's (LON:CTEC) 32% Undervaluation?
- Aug -04 - ConvaTec Group First Half 2023 Earnings: EPS Misses Expectations
- May -22 - FTSE closes in the green, Wall Street mixed as traders monitor US debt talks
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Advanced Wound Care
Expected Growth : 6.5 %
What the company do ?
Advanced Wound Care from ConvaTec Group Plc provides innovative solutions for wound healing, including dressings, debridement, and negative pressure wound therapy.
Why we expect these perspectives ?
ConvaTec's Advanced Wound Care segment growth is driven by increasing demand for chronic wound management, rising prevalence of diabetes and obesity, growing adoption of advanced wound care technologies, and expansion into emerging markets. Additionally, strategic acquisitions and investments in R&D have enhanced the company's product portfolio, further fueling growth.
Segment n°2 -> Ostomy Care
Expected Growth : 6.2 %
What the company do ?
Ostomy Care from ConvaTec Group Plc provides innovative medical products and services for people with ostomies, offering a range of pouching systems and accessories for a better quality of life.
Why we expect these perspectives ?
ConvaTec's Ostomy Care segment growth of 6.2% is driven by increasing prevalence of chronic diseases, advancements in ostomy products, and rising awareness about ostomy care management. Additionally, strategic acquisitions, expansion into emerging markets, and a growing demand for home healthcare services contribute to the segment's growth.
Segment n°3 -> Continence Care
Expected Growth : 6.8 %
What the company do ?
ConvaTec's Continence Care segment offers products for people with urinary incontinence, including catheters, drainage bags, and accessories, promoting independence and dignity.
Why we expect these perspectives ?
ConvaTec's Continence Care segment growth of 6.8% is driven by increasing demand for catheters and ostomy care products, fueled by an aging population and rising prevalence of chronic diseases. Additionally, expansion into emerging markets, product innovation, and strategic acquisitions contribute to the segment's growth.
Segment n°4 -> Infusion Care
Expected Growth : 7.2 %
What the company do ?
Infusion Care from ConvaTec Group Plc provides innovative infusion systems and services for patients with chronic conditions, offering discreet and convenient therapy management.
Why we expect these perspectives ?
ConvaTec's Infusion Care segment growth of 7.2% is driven by increasing demand for home infusion therapies, expansion in emerging markets, and strategic product launches. Additionally, the segment benefits from a growing elderly population, rising prevalence of chronic diseases, and a shift towards outpatient care, leading to increased adoption of infusion care products.
Segment n°5 -> Hospital Care
Expected Growth : 6.9 %
What the company do ?
Hospital Care from ConvaTec Group Plc provides medical solutions for wound care, ostomy care, and continence care to healthcare professionals and patients.
Why we expect these perspectives ?
ConvaTec Group Plc's Hospital Care segment growth of 6.9% is driven by increasing demand for advanced wound care products, expansion into emerging markets, and strategic partnerships with healthcare providers. Additionally, investments in research and development have led to innovative product launches, further boosting growth.
Convatec Group Plc Products
| Product Range | What is it ? |
|---|---|
| Ostomy Care | ConvaTec's Ostomy Care products are designed to help individuals with ostomies manage their condition with confidence and discretion. The range includes one-piece and two-piece pouching systems, skin barriers, and accessories. |
| Wound Therapeutics | ConvaTec's Wound Therapeutics products are designed to promote wound healing and tissue repair. The range includes dressings, gels, and other topical treatments. |
| Continence and Critical Care | ConvaTec's Continence and Critical Care products are designed to help individuals manage urinary incontinence and other urological conditions. The range includes catheters, drainage bags, and other accessories. |
| Infusion Devices | ConvaTec's Infusion Devices are designed to provide safe and reliable infusion therapy for patients. The range includes infusion sets, syringes, and other accessories. |
ConvaTec Group Plc's Porter Forces
Threat Of Substitutes
ConvaTec Group Plc operates in the medical technology industry, which is characterized by a moderate threat of substitutes. While there are alternative products and services available, they are not perfect substitutes, and ConvaTec's products have a unique value proposition.
Bargaining Power Of Customers
ConvaTec Group Plc's customers are primarily healthcare providers and patients, who have limited bargaining power due to the specialized nature of ConvaTec's products and services.
Bargaining Power Of Suppliers
ConvaTec Group Plc's suppliers are primarily manufacturers of raw materials and components, who have some bargaining power due to the specialized nature of their products. However, ConvaTec's scale and diversification mitigate this power.
Threat Of New Entrants
The medical technology industry has high barriers to entry, including regulatory hurdles and significant research and development investments, which limit the threat of new entrants.
Intensity Of Rivalry
The medical technology industry is highly competitive, with several established players competing for market share. ConvaTec Group Plc faces intense competition from companies such as Johnson & Johnson, Medtronic, and 3M.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 43.67% |
| Debt Cost | 6.94% |
| Equity Weight | 56.33% |
| Equity Cost | 6.94% |
| WACC | 6.94% |
| Leverage | 77.53% |
ConvaTec Group Plc : Quality Control
ConvaTec Group Plc passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TECN.SW | Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business … |
| YPSN.SW | Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and … |
| AMP.MI | Amplifon S.p.A. retails hearing care products and services that help people rediscover various emotions of sound. The company offers ampli-easy, ampli-mini, ampli-connect, and ampli-energy hearing devices. It also provides fitting … |
| EKTA-B.ST | Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac … |
| FIE.DE | Fielmann Aktiengesellschaft, together with its subsidiaries, engages in the investment in and operation of optical and hearing aid businesses. The company manufactures and sells visual aids and other optical products, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Fielmann
A-Score
1-Year Total Return ->
🥈
Elekta
A-Score
1-Year Total Return ->
🥉
Ypsomed
A-Score
1-Year Total Return ->
4
ConvaTec
A-Score
1-Year Total Return ->
5
Amplifon
A-Score
1-Year Total Return ->
6
